Search Results

Alpha-9 Oncology Initiates Phase 1 Clinical Trial of GRPR-Targeted Radiotherapy, First Patient Dosed

Alpha-9 Oncology, a U.S. clinical-stage radiopharmaceutical company, recently announced that the first patient has been dosed in its Phase 1 clinical trial evaluating two GRPR-targeted radiopharmaceuticals. The study involves the actinium-225-labeled compound 225Ac-A9-0642 and the lutetium-177-labeled compound 177Lu-A9-0631, primarily enrolling patients with breast cancer and other solid tumors, with data expected to be released by the end of 2027. According to the company, both 225Ac-A9-0642 and 177Lu-A9-0631 target the gastrin-releasing peptide receptor (GRPR). GRPR is considered a solid tumor-associated target with potential clinical value in breast cancer and other solid tumors. 225Ac-A9-0642 is Alpha-9's first actinium-225 GRPR-targeted compound to enter clinical evaluation...

2026-09-09

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

New Analytical Laboratory Completed at Oak Ridge to Support U-233 Cleanup and Medical Isotope Supply

The U.S. Department of Energy Oak Ridge Environmental Management Office (OREM) and its contractor Isotek Systems completed installation of a new analytical laboratory at Oak Ridge National Laboratory (ORNL) on August 25, 2026. The laboratory will support ORNL's highest-priority environmental cleanup project and accelerate delivery of critical medical isotope materials for cancer treatment research. Isotek Systems is responsible for removing the U.S. uranium-233 inventory stored at Oak Ridge National Laboratory. Uranium-233 was primarily developed in the 1950s and 1960s, initially intended for use as nuclear reactor fuel, but was later proven unsuitable as a commercial fuel source...

2026-08-26

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals

South Korea's domestic production project for actinium-225 (Ac-225), a radioisotope used in next-generation cancer treatment, is expected to resume next year after being stalled for more than a year. Funding was secured in the first half of this year, and the Korea Institute of Radiological & Medical Sciences (KIRAMS) plans to complete facility construction and trial production before launching full-scale production in the second half of next year, aiming to alleviate the raw material shortage facing domestic clinical research and radiopharmaceutical development. KIRAMS is affiliated with the Ministry of Science and ICT. The institute received approval from the Nuclear Safety and Security Commission in May last year to produce Ac-225 using a cyclotron. The project first entered the review process in 2018 and took seven years to gain approval, with initial production originally planned by the end of last year. However, work on upgrading production facilities and procuring equipment was suspended after approximately 2 billion KRW in budget was not approved during parliamentary review.

2026-08-10

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

TerraPower Isotopes to Donate Actinium-225 via Oncidium Foundation to Support Cancer Treatment Accessibility

TerraPower Isotopes (TPI), a subsidiary of U.S. nuclear innovation company TerraPower, announced on July 29 that it will coordinate the donation of the rare medical isotope actinium-225 (Ac-225) through the Oncidium Foundation to support economically disadvantaged cancer patients in accessing targeted radionuclide therapy. The Oncidium Foundation is a non-profit organization dedicated to promoting global access to targeted radionuclide cancer treatments. Its RLT-Connect program aims to help financially challenged patients access relevant therapies, reducing treatment disparities caused by geographic and economic conditions. This donation also marks TPI's entry into Oncidium's collaborative ecosystem of radioisotope suppliers, medical practitioners...

2026-07-30